This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Array Biopharma Inc., Mirati Therapeutics, Inc.. Active years: 2026.
Company Filing History:
2 out of 333 
2 out of 44 
Years Active: 2026
Title: James Francis Blake: Innovator in KRAS G12D Inhibitors
Introduction
James Francis Blake is a notable inventor based in Longmont, Colorado. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit KRas G12D. His work is crucial in the ongoing fight against cancers associated with this mutation.
Latest Patents
James Francis Blake holds a patent related to KRAS G12D inhibitors. The present invention pertains to compounds that inhibit the activity of KRas G12D. It also includes pharmaceutical compositions comprising these compounds and methods of use for them. This innovation represents a significant advancement in targeted cancer therapies.
Career Highlights
Throughout his career, Blake has worked with prominent companies in the biotechnology sector. He has been associated with Mirati Therapeutics, Inc. and Array Biopharma Inc. These experiences have allowed him to contribute to groundbreaking research and development in cancer treatment.
Collaborations
James has collaborated with talented individuals in his field, including Sherif Hosam Hassanien and Matthew Arnold Marx. Their combined expertise has furthered the development of innovative solutions in the pharmaceutical industry.
Conclusion
James Francis Blake's work in developing KRAS G12D inhibitors showcases his commitment to advancing cancer treatment. His contributions to the field are invaluable and highlight the importance of innovation in medicine.